Neurotech startup Elemind emerges with $12m for drug-free ‘electric medicine’

Big investors back wearable neurotech delivering ‘instantaneous neuromodulation’ to induce sleep, boost memory, and increase pain thresholds.

Neurotechnology company Elemind has emerged from stealth mode, securing $12 million in seed funding to advance its AI-enhanced neurotech wearable. The Cambridge, MA-based company is on a mission to enhance various aspects of human health using non-invasive, proactive stimulation of brainwaves.

Village Global, a VC firm backed by the likes of Jeff Bezos and Bill Gates, was the first investor in the company. Other investors in the round include LDV Partners, MIT’s investment fund, and the founders of a host of tech companies including Skype and Nest.

Founded in 2019, Elemind, which refers to its approach as “electric medicine,” aims to provide personalized and adaptive options for treating health issues without resorting to pharmaceuticals. Leveraging a “breakthrough” algorithm, the company’s wearable neurotech device monitors individual brainwaves and responds with tailored electrical stimulation, guiding brainwaves to change their behavior in real-time.

“Each brain is unique and constantly changing, so we leverage AI and ML to optimize stimulation parameters to achieve the desired state the fastest,” said Dr David Wang, CTO of Elemind. “You can think about it like noise cancellation for the mind – our technology uses phase-locking auditory stimuli to align precisely with the user’s brainwaves and steer them to a different frequency associated with a different state.”

Elemind’s adaptive approach fine-tunes stimulation based on the body’s response until the desired state is achieved, delivering health and wellness benefits, and offering what the company claims will be a smarter, more targeted, and natural alternative to pharmaceuticals.

“Chemical drugs affect the entire body, often leading to unwanted side effects,” said Meredith Perry, CEO of Elemind. “Elemind offers a non-chemical, direct, and on-demand solution that learns and dynamically adjusts to each person. We’re the first and only company able to precisely guide and redirect brainwaves in real-time.”

A number of clinical trials appear to support the company’s claim that its tech holds potential across various neurological conditions, with studies showing it can induce sleep up to 74% faster, suppress tremors, boost memory, increase pain thresholds, and enhance sedation.

Elemind plans to unveil its first product in the coming months. As a “general wellness” device, the company says it will not be subject to FDA regulation.

Elemind’s team comprises neuroscientists, doctors, and entrepreneurs from institutions including MIT, Imperial College London, Harvard Medical School, and the University of California at Berkeley. The company boasts three key patents covering its core signal processing algorithms and dynamic neurostimulation techniques.